<DOC>
	<DOC>NCT01180049</DOC>
	<brief_summary>This study will compare the effectiveness and safety of two different doses of temsirolimus (Torisel).</brief_summary>
	<brief_title>Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Have confirmed mantle cell lymphoma diagnosis. Have measurable disease. Have received at least 2 prior treatment, which may include stem cell transplant. Have adequate organ and bone marrow function. There are other criteriaplease discuss with your doctor. Had any prior treatment with temsirolimus or mTOR inhibitor. Had allogeneic stem cell transplant within last 6 months and on immunosuppressive therapy. Has active or untreated brain or central nervous system metastases. There are other criteriaplease discuss with your doctor.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>non-Hodgkin lymphoma (NHL)</keyword>
	<keyword>temsirolimus</keyword>
</DOC>